Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer

STATUS

Recruiting
End date

Dec 28, 2026
participants needed

74
sponsor

Vejle Hospital

Send

Updated on 19 February 2024

See if I qualify

cancer

hysterectomy

platelet count

renal function

metastasis

neutrophil count

oxaliplatin

adenocarcinoma

oophorectomy

bevacizumab

capecitabine

fluorouracil

leucovorin

serum bilirubin

bilateral oophorectomy

hormonal contraception

kidney function tests

folfox regimen

kidney function test

serum bilirubin level

adenocarcinoma of colon

metastatic colorectal cancer

adenocarcinoma of the colon

tubal occlusion

transient ischemic attack

investigational treatment

experimental therapy

tocotrienol

colorectal cancer

incision biopsy

disseminated cancer

cancer metastatic

Summary

This double blind, randomized phase II trial will investigate whether the addition of tocotrienol will improve the effect and lower the toxicity of standard chemotherapy and bevacizumab. Half of the patients will receive tocotrienol and the other half placebo. Treatment is planned for a period of maximum six months and will be discontinued earlier in case of progression or unacceptable toxicity.

Details

Condition	Colorectal Cancer Metastatic
Age	18years - 100years
Treatment	Placebo, Bevacizumab, Capecitabine, Fluorouracil, Oxaliplatin, Calcium folinate, Tocotrienol
Clinical Study Identifier	NCT04245865
Sponsor	Vejle Hospital
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Histopathologically verified adenocarcinoma of the colon or rectum
	Metastatic disease
	Planned treatment with FOLFOX or capecitabine combined with bevacizumab
	Evaluable disease according to RECIST 1.1
	Performance status 0-2
	Expected survival 3 months
	Patient acceptance to collection of blood samples for translational research
	Age 18 years
	Contraception during and 6 months after last dose for women of childbearing potential (less than one year amenorrhea and not undergone hysterectomy, bilateral salpingectomy or bilateral oophorectomy) and for male patients with a fertile partner. Hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or sexual abstinence is accepted
	Adequate bone marrow function, liver function, and renal function (within 7 days prior to inclusion)
	WBC 3.0 x 109/l or neutrophils (ANC) 1.5 x 10^9/l
	Platelet count 100 x 10^9/l
	Hemoglobin 6.0 mmol/l
	Serum bilirubin 2.0 x ULN
	Serum transaminase 2.5 x ULN
	Serum creatinine 1.5 ULN
	Urine dipstick for protein 2+, if the dipstick shows protein 2+, 24 hour urine testing must be performed and show protein contents 1g
	Written and orally informed consent
Exclusion Criteria
	Other active malignant disease within 5 years prior to inclusion in the study
	Other experimental therapy within 28 days prior to treatment initiation
	Underlying medical disease not adequately treated
	Surgery, including open biopsy, within 4 weeks prior to first dose of bevacizumab
	Cerebral vascular attack, transient ischemic attack or subarachnoid hemorrhage within six months before start of treatment
	Bleeding tumor
	Pregnant or breastfeeding women
	Fertile patients not willing to use effective methods of contraception during treatment and for six months after end of treatment
	Hypersensitivity to one or more active substances or auxiliary substances

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

bilateral oophorectomy

hormonal contraception

kidney function tests

folfox regimen

kidney function test

serum bilirubin level

adenocarcinoma of colon

metastatic colorectal cancer

adenocarcinoma of the colon

tubal occlusion

transient ischemic attack

investigational treatment

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer